Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07298343) titled 'Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease' on Dec. 17, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Dr. Falk Pharma GmbH
Condition:
Celiac Disease
Intervention:
Drug: ZED1227 + SIGE
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: June 10, 2024
Target Sample Size: 356
Countries of Recruitment:
Germany
To know more, visit https://clinicaltrials.gov/study/NCT07298343...